?????????????.??????????????????????????????????????102 However, many groups are advocating for your incorporation of novel markers, for instance a sophisticated karyotype55 or epigenetic subsets, 27,28 into clinical practice. These novel prognostic and/or predictive products will have to be validated in cohorts of patients addressed with specific